Black Diamond Therapeutics Company

Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery and development of small-molecule. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform namely, Mutation-Allostery-Pharmacology which is targeting mutations in cancer. Black Diamond focused on the discovery and development of precision medicines for cancer that is directed against a novel class of allosteric mutant oncogenes. The company targets undrugged mutations in patients with genetically defined cancers for whom limited treatment options currently exist. It is built upon a deep understanding of cancer genetics, protein structure and function, and medicinal chemistry.
Industry: End-to-end Drug Development
Headquarters: Cambridge, Massachusetts, United States
Founded Date: 2017-01-01
Employees Number: 11-50
Funding Status: IPO
Investors Number: 16
Total Funding: 197100000
Estimated Revenue: $10M to $50M
Last Funding Date: 2019-12-05
Last Funding Type: Series C

Visit Website
info@bdtherapeutics.com
Register and Claim Ownership